Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study
-
Altmetric Citations
Hartnett, P; Buck, M; Beale, Phillip; Goldrick, A; Allan, S; Fitzharris, B; de Souza, P; Links, M; Kalimi, G; Davies, T; Stuart-Harris, Robin
Description
Gemcitabine and oxaliplatin have shown single-agent activity in relapsed ovarian cancer. This combination was used to determine response rates, time-to-event efficacy measures, and toxicity in patients with recurrent ovarian cancer. Patients with prior platinum-based chemotherapy who had measurable lesions and/or elevated CA-125 levels were identified as group A (platinum-refractory/platinum-resistant patients) and group B (platinum-sensitive patients). All patients received gemcitabine 1000...[Show more]
Collections | ANU Research Publications |
---|---|
Date published: | 2007 |
Type: | Journal article |
URI: | http://hdl.handle.net/1885/60158 |
Source: | International Journal of Gynecological Cancer |
DOI: | 10.1111/j.1525-1438.2007.00763.x |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Hartnett_Phase_II_study_of_gemcitabine_2007.pdf | 136.41 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator